GET A PIECE OF CANCERVAX
A Breakthrough Universal Cancer Vaccine
$348,402 Raised
Offering Circular | Selected Risks Related to this Offering | SEC EDGAR Page
REASONS TO INVEST
- According to the World Health Organization, cancer is the second leading cause of death globally. Cancer vaccines, also known as cancer immunotherapies, are some of the latest weapons designed to fight cancer. CancerVAX treatments will be formulated to use the body’s own immune system to fight cancer, usually with milder side effects and more targeted than existing treatments, such as chemotherapy. The cancer immunotherapy market is expected to grow to $196 billion by 2030 (according to Bloomberg Business).*
- The company has two research programs with a team of MDs and PhDs at the renowned cancer center at UCLA: (1) a novel universal cancer vaccine targeting multiple cancers, and (2) a single disease immunotherapy targeting Ewing sarcoma, a rare but deadly cancer that primarily affects young children. CancerVAX has exclusive rights to license any intellectual property and technology (patents) that may result from the research. UCLA is a top-ranked university known for its cancer research and medical school.
- CancerVAX is headed by CEO Ryan Davies, who has an extensive background in the biotech industry including co-founding several biotech companies including, a nitric oxide topical wound-care company (Advanox), a medical device company (Purgo Scientific), and an antibiotic drug development company (Curza).
- CancerVAX has previously raised $2 million of seed funding.
THE Pitch
Detect. Mark. Kill.
CancerVAX is developing a universal cancer vaccine (currently in the conceptual testing stage) that will use the body’s immune system to fight off cancer. This process, known as cancer immunotherapy, is a state-of-the-art treatment that the company believes will detect, mark, and kill only cancer cells, while leaving the healthy cells alone.
CancerVAX’s research is performed by an experienced team of MDs and PhDs at UCLA. The company has two research agreements with UCLA as well as an option agreement, granting CancerVAX the exclusive rights to license all intellectual property and technology (patents) developed under the research agreements.
CancerVAX is headed by CEO Ryan Davies, who has an extensive background in the biotech industry including co-founding several biotech companies including a nitric oxide topical wound-care company product (Advanox), a medical device company (Purgo Scientific), and an antibiotic drug development company (Curza).
THE Problem & our solution
Get Better, Without Feeling Worse
Cancer is the second leading cause of death in the world – responsible for 10 million deaths in 2020 alone. (Source) Even in the U.S., 1.8 million new cases of cancer were diagnosed in just that one year. (Source)
However, cancer treatments still haven’t progressed past the options of surgery, chemotherapy, and radiation, which have extreme, life-long side effects. In addition to being toxic and harmful, treatments like chemotherapy can be expensive, and difficult for most people to afford.
A Universal Cancer Vaccine
CancerVAX is developing a universal cancer vaccine that targets multiple types of cancer and improves the recovery process. Much like how the COVID-19 vaccine trains the body to recognize and destroy coronavirus, CancerVAX’s vaccine would similarly leverage the body’s immune system to detect, mark, and kill cancer cells.
Most immunotherapy treatments kill bad cancer cells while also killing good, healthy cells simply because the natural cell markers they use as targets appear on both cancer and healthy cells. CancerVAX’s universal cancer vaccine would force cancer cells to reveal a unique marker, so they can be targeted and killed with a high level of precision, while leaving the healthy cells intact. CancerVAX believes this new method of targeting and destroying cancer with the body’s own immune system will treat cancer in a safe, non-toxic, and most importantly, highly targeted way.
Treating Kid’s Cancer - Ewing sarcoma
CancerVAX is also developing a disease-specific immunotherapy targeted at treating Ewing sarcoma, a rare but deadly bone and soft tissue cancer that primarily affects children and young adults, and for which there is no current FDA approved treatment for recurrence.
The company has entered into a sponsored research agreement with the University of California at Los Angeles (UCLA) to develop effective immunotherapies, such as CAR T-cell and monoclonal antibodies, for Ewing sarcoma.
THE market & our traction
A Never-Ending Need
Currently, over 100 types of cancers exist. In 2015 approximately $183 billion was spent on cancer health care, in the U.S. alone; that number is projected to grow to $246 billion by 2030. (Source)
CancerVAX raised an initial seed round of $2 million and has rights to three patent applications surrounding Universal Cancer Vaccine and Ewing sarcoma technologies. The company also has exclusive rights to license new intellectual property that is developed under the two CancerVAX research programs with UCLA, which offers other potential revenue streams.
why invest
Let's Beat Cancer
Pharmaceutical research is booming from the effects of the COVID-19 pandemic, where the medical community learned how to use mRNA to recognize and fight specific disease states. A similar concept is being applied by CancerVAX to create a vaccine with the purpose of using a patient’s immune system to detect, mark, and kill cancer.
The CancerVAX business model involves partnering with experienced cancer research institutions, like UCLA, to develop new life-changing drugs, followed by future plans to license or sell the company’s drugs, or license technologies to major pharmaceutical companies.
As a biotech company, CancerVAX’s goal is to create value for our company and our shareholders with every step of incremental success we make on the path to FDA approval. From discovery, to optimization, to pre-clinical trials, and additional future phases (phase 1 clinical trials, phase 2 clinical trials, phase 3 clinical trials), every step is a value inflection point that CancerVAX believes could increase the company’s value and bring them one step closer to curing cancer.
Join CancerVAX and invest in its breakthrough technologies to help beat cancer!
AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT.
THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT CAN BE FOUND HERE.
CROWDCHECK VERIFIED REPORT CAN BE FOUND HERE.
THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.
ABOUT
HEADQUARTERS
351 Paseo Nuevo, Floor 2
Santa Barbara, CA 93101
WEBSITE
View Site
CancerVAX is a pre-clinical, pre-revenue biotech company developing a universal cancer vaccine that uses the body's immune system to fight cancer.
TEAM
Ryan Davies
Chief Executive Officer
Byron Elton
Chief Marketing Officer
TERMS
CancerVax
Overview
PRICE PER SHARE
$2
DEADLINE
May 31, 2024
VALUATION
$61.02M
FUNDING GOAL
$500 - $10M
Breakdown
MIN INVESTMENT
$500
MAX INVESTMENT
$1,000,000
MIN NUMBER OF SHARES OFFERED
250
MAX NUMBER OF SHARES OFFERED
5,000,000
OFFERING TYPE
Equity
ASSET TYPE
Common Stock
SHARES OFFERED
Common Stock
Maximum Number of Shares Offered subject to adjustment for bonus shares
*Maximum number of shares offered subject to adjustment for bonus shares. See bonus info below.
Investment Incentives and Bonuses*
Amount-Based:
Tier 1 | $5,000+
Invest $5,000+ and receive 5% bonus shares.
Tier 2 | $10,000+
Invest $10,000+ and receive 7% bonus shares.
Tier 3 | $25,000+
Invest $25,000+ and receive 10% bonus shares.
Tier 4 | $50,000+
Invest $50,000+ and receive 15% bonus shares.
Tier 5 | $100,000+
Invest $100,000+ and receive 20% bonus shares.
The 10% StartEngine Owners' Bonus
CancerVax will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $2.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $2.00. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested (if any). Eligible investors will also receive the Owner’s Bonus in addition to the amount based bonus.
*All perks occur when the offering is completed.
NEW UPDATES
09.22.23
IMPORTANT CEO UPDATE About Bonus Shares
Ryan Davies, CEO of CancerVAX, recently thanked investors and urged everyone to take advantage of valuable investor perks.
With up to 30% bonus CancerVAX shares available, the more an investor commits, the larger discount awarded in the form of bonus shares!
“Our investors are family to us and we want them to earn bonus shares which is why we have made it straightforward and easy,” Ryan stated.
“We created 5 tiers that allow each investor to pick a level that works for them,” Ryan explained, “and earn valuable bonus shares with as little as a $500 investment by being a StartEngine Owner’s Bonus member, which awards 10% bonus shares.”
CancerVAX is revolutionizing cancer treatment using the body's immune system to fight cancer.
Amount-Based Bonus Shares:
- Tier 1 | Invest $5,000+ and receive 5% bonus shares.
- Tier 2 | Invest $10,000+ and receive 7% bonus shares.
- Tier 3 | Invest $25,000+ and receive 10% bonus shares.
- Tier 4 | Invest $50,000+ and receive 15% bonus shares.
- Tier 5 | Invest $100,000+ and receive 20% bonus shares.
10% StartEngine Owners' Bonus + Amount-Based Bonus Shares = Up to 30% Bonus Shares.
Each week our research teams make progress in their mission.
We invite you to join us and earn some BONUS SHARES.
Help us in the fight against cancer by investing in CancerVAX.
For more information about CancerVAX, please visit https://www.cancervax.com
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
09.21.23
HOPE FOR PEDIATRIC CANCER
There may be hope for pediatric cancer on the horizon as scientists move ever closer to a treatment for Ewing sarcoma, a pervasive and difficult-to-treat cancer that attacks bones and soft tissue, more common in teens and young adults over any other age group.
Recently, the research team found the silver bullet: a protein biomarker present on most Ewing sarcoma tumors. Now, they’re targeting that biomarker in the quest to help cancer patients’ immune systems recognize, attack and destroy Ewing sarcoma.
In collaboration with a team of researchers and physicians at UCLA, CancerVAX has been working on developing treatments for Ewing sarcoma. It all started with the identification of a common protein biomarker present on the surface of more than 90% of Ewing sarcoma tumors.
This work is giving rise to treatments that will help spur cancer patients’ own immune systems into action to fight against this otherwise difficult-to-terminate cancer. The treatments could enter early testing phases as early as Spring 2024.
For patients fighting Ewing sarcoma, any step forward towards a new viable treatment is a positive one. And for the youngest of these, it could mean a new opportunity to live free from the tubes, needles and stress of cancer, and to live strong within their own bodies.
For more information about CancerVax, please visit https://www.cancervax.com
This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
ALL UPDATES
Stack Owner's Bonus & Rewards!
Members get an extra 10% shares in addition to rewards below!
REWARDS
$500
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$5,000
Tier 1
Invest $5,000+ and receive 5% bonus shares.
$10,000
Tier 2
Invest $10,000+ and receive 7% bonus shares.
$25,000
Tier 3
Invest $25,000+ and receive 10% bonus shares.
$50,000
Tier 4
Invest $50,000+ and receive 15% bonus shares.
$100,000
Tier 5
Invest $100,000+ and receive 20% bonus shares.
JOIN THE DISCUSSION
0/2500
Christopher Flowers
3 months ago
I need to see links to the relevant 3 patents you say you hold before deciding whether to invest in this project. As a cancer specialist who has worked at UCLA and UCSF I need more information to complete due diligence
1
1
Al asparisi@gmail.com
3 months ago
I concur with other commenting on the Valuation. If the valuation of $60M made any sense, VC's would have jumped on this like pigs in a mud puddle. This company has nothing but a pipe dream. I could have made up the same pipe dream. Here let's try this: Let's solve Heart disease by creating a "vaccine" that eats cholesterol build up in your arteries. Am I now worth $60M ?? The only worth this company has now, is it's research into Ewing Sarcoma's. Any investor should be aware that if this company is successful, it will be a decade or more. So be aware that there is a 95% chance you will lose 100% of your investment. With that said, I hope companies like this are successful, but the risk reward, especially at this valuation, is not for me.
1
0
Timothy Shroyer
3 months ago
A $61MM valuation - pre-clinical and pre-revenue? C'mon guys. This is ridiculous. This is going to be an extremely long haul. You should be at $5-10MM.
0
0
Francis Erdman
3 months ago
A friend's mother passed from pancreatic cancer a few years ago and as a "hail Mary" shortly before her death they did immunotherapy which had no impact - more recently, this same friend of mine had a friend who died of melanoma, after, again, a failed "hail Mary" of immunotherapy. Those are just two anecdotes I know of, but in general immunotherapy seems like a last ditch money waster by people in late stage cancer - if it were me, I'd skip the pointless therapies and let that money go to my heirs, rather than trying experimental stuff right down to the last minute. That's a personal decision obviously but the point is, immunotherapy does not work, has never worked, and this is really just Elizabeth Holmes territory trying to profit from guillable investors and/or desperate cancer patients, to be blunt. Probably why it does not work is the immune system largely evolved to fight nucleic-acid based pathogens (so, viruses, bacteria) but disease causing agents that are not nucleic-acid based (prions, for example), the immune system just isn't experienced enough to handle - and same with cancer - by definition it is not a foreign agent (like a virus) it is simply the body's own cells running amuk - the immune system cannot handle that, just as my portfolio cannot handle Theranos II, thank you.
1
0
Justin Horvath
4 months ago
Hi,
Why are you worth $60 million when you don’t even have a drug developed? In addition, I am assuming you haven’t even done any testing on said drug to see if it works, since of course it’s not developed.
For a point of reference, Oncolyze another cancer biotech company on this platform, values themselves at $30 million and has a developed drug OM-301, which was declared orphan drug status by FDA. In addition they done some testing on it for its efficacy in animals.
So why are you worth more when it seems you have done so less? Is there something I am missing here?
0
0
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
Richard Negvesky
2 months ago
1
0